Beyene Melak Gedamu, Teferra Solomon, Fenta Teferi G
Department of Pharmacy, Addis Ababa University, Addis Ababa, ETH.
Department of Medicine, Addis Ababa University, Addis Ababa, ETH.
Cureus. 2024 Sep 10;16(9):e69065. doi: 10.7759/cureus.69065. eCollection 2024 Sep.
Background Metabolic syndrome (MetS) encompasses a group of risk factors that increase the likelihood of developing cardiovascular diseases, thereby increasing the mortality rate. Second-generation antipsychotics (SGAs) are known for these side effects. This study aimed to determine the prevalence of MetS and its associated factors at Amanuel Mental Specialized Hospital. Methods A cross-sectional study was conducted from October 3, 2022, to August 31, 2023. Fasting blood sugar and lipid analysis were performed using the Dimension® EXL™ 200 Integrated Chemistry System (Siemens Healthineers, Malvern, PA, USA). A diagnosis of MetS was established using the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria. IBM SPSS Statistics for Windows, Version 25 (Released 2017; IBM Corp., Armonk, NY, USA) was used for analysis. A binary logistic regression model was employed, and a p-value less than 0.05 was considered significant. Results A total of 271 participants were enrolled in the study. Most subjects were male (90%) and had a mean age of 34.2 years, with an SD of 10.5. Most participants (70.8%) had abnormal waist circumference, followed by lower high-density lipoprotein cholesterol (HDL-C) at 42.8%. The prevalence of MetS was 35.8%. Gender (being female) (adjusted odds ratio or AOR 3, 95% CI: 1.2-7.4; p = 0.02) and olanzapine use (AOR 2.2, 95% CI: 1.3-3.7; p = 0.005) were predictors of MetS. Conclusions MetS is highly prevalent in patients treated with SGAs. Being female and olanzapine use were predictors of MetS. Clinicians managing these patients should screen and monitor the metabolic components used to diagnose MetS.
背景 代谢综合征（MetS）包含一组增加患心血管疾病可能性从而提高死亡率的危险因素。第二代抗精神病药物（SGAs）因这些副作用而闻名。本研究旨在确定阿马努埃尔精神专科医院代谢综合征的患病率及其相关因素。方法 于2022年10月3日至2023年8月31日进行了一项横断面研究。使用Dimension® EXL™ 200综合化学系统（西门子医疗，美国宾夕法尼亚州马尔伯勒）进行空腹血糖和血脂分析。采用改良的美国国家胆固醇教育计划成人治疗小组第三次报告（NCEP ATP-III）标准诊断代谢综合征。使用IBM SPSS Statistics for Windows，版本25（2017年发布；IBM公司，美国纽约州阿蒙克）进行分析。采用二元逻辑回归模型，p值小于0.05被认为具有统计学意义。结果 共有271名参与者纳入研究。大多数受试者为男性（90%），平均年龄为34.2岁，标准差为10.5。大多数参与者（70.8%）腰围异常，其次是高密度脂蛋白胆固醇（HDL-C）降低，占42.8%。代谢综合征的患病率为35.8%。性别（女性）（调整后的优势比或AOR为3，95%置信区间：1.2 - 7.4；p = 0.02）和使用奥氮平（AOR为2.2，95%置信区间：1.3 - 3.7；p = 0.005）是代谢综合征的预测因素。结论 代谢综合征在接受第二代抗精神病药物治疗的患者中非常普遍。女性和使用奥氮平是代谢综合征的预测因素。管理这些患者的临床医生应筛查和监测用于诊断代谢综合征的代谢成分。
